MET and melanoma: Specifically, lung cancer patients with MET exon 14 skipping are responsive to MET inhibitors despite not having other activating alterations [39], while melanoma patients expressing a BRAF isoform lacking exons 4–8, which encodes for the RAS binding domain, exhibit resistance to BRAF inhibitors [40].